Table 3

Demographic and clinical characteristics for the 157 HCV infected patients studied, grouped by HFE genotype

VariableHis63Asp/Cys282Tyr (n=8)Cys282Tyr/WT* (n=26)His63Asp/WT* (n=33)WT/WT* (n=90)p Value
Values are median (range) unless otherwise stated
*WT, wild type; IVDU, intravenous drug use.
Age (y)38 (25–54)34 (23–61)35 (23–61)36.5 (42–70)0.53
Sex (male:female) 6:219:718:1556:340.45
Age at acquisition of HCV (y)23 (14–35)20 (13–37)24 (14–54)21 (13–51)0.31
Duration of HCV infection at time of biopsy (y) 8 (3–25)15 (5–39)12 (6–23)15 (5–28)0.26
Alcohol consumption at biopsy (U/week) (mean (SD))12 (13.7)12 (16) 8 (11)15 (35)0.70
Past history of excess alcohol consumption (No (%)) 3 (37)14 (54)10 (30)25 (34)0.11
Previous interferon therapy (No (%)) 3 (37) 4 (15) 3 (9)15 (17)0.26
Route of HCV infection (n)
    IVDU 42015390.19
    Blood products 3 2 923
    Other 1 4 928
Serum HCV RNA positive (n) 8253289
    Genotype 1 31315330.94
    Genotype 2 1 3 4 9
    Genotype 3 4 91346
    Genotype 4 0 0 0 1